alexa CalAsia Pharmaceuticals Inc

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

CalAsia Pharmaceuticals Inc

CalAsia Pharmaceuticals, Inc. is an employee owned early stage pharmaceutical company concentrates on the rapid discovery of drug-like small molecules by using its core technologies. This was founded in 2009 & located at San Diego. Allan E. Rubensteinis the present MD of CalAsia Pharmaceuticals,Inc. Its core technology platform effectively combines functional fragment screening with X-ray crystallography co-crystallization guided by a streamlined structure-based design approach to rationally design and synthesize New Chemical Entities (NCEs) with drug-like properties. CalAsia also employs an academically-advanced stem cell technology platform to evaluate lead drug candidates for proof of concept using patient-derived human induced pluripotent stem cells (iPSC). CalAsia team has decades of drug discovery experience, including exceptional training and acquired skills in sophisticated structure-based drug design, as evidenced by a prominent history of involvement with numerous successful drug discovery programs, which have produced multiple clinical candidates, as well as one marketed drug. CalAsia's Services: The CalAsia team provides its core expertise, which includes cloning, recombinant protein expression (E. coli, baculovirus & yeast), protein purification, biochemical assays, cellular assays, fragment screening, X-ray crystallography co-crystallization, and structure-based drug design methodology to the drug discovery community through contract research.